RMD SEC-arkiveringar - ResMed Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

LEI	529900T3QE5253CCXF22
CIK	943819

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ResMed Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

May 26, 2026	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission Fi SD SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) Mic
May 26, 2026	EX-1.01	For the Reporting Period from January 1, 2025 through December 31, 2025 EX-1.01 Exhibit 1.01 Exhibit 1.01 — Conflict Minerals Report of Resmed Inc. For the Reporting Period from January 1, 2025 through December 31, 2025 ResMed Inc., (“Resmed”) prepared this conflict minerals report for the reporting period from January 1, 2025 through December 31, 2025 to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“rule”). The rule requires Resmed to
May 1, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
May 1, 2026	EX-10.1	Component Exhibit 10.1 April 24, 2026 Aaron Bloomer Dear Aaron, It gives me great pleasure to extend to you this offer of employment with Resmed, Inc. (referred to as “the Company” hereafter) based on the terms and conditions set forth in this letter. This offer is for the position of Chief Financial Officer. You will be responsible for such duties as are normally associated with this position and as may be
April 30, 2026	EX-99.1	Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor EX-99.1 Exhibit 99.1 For Investors For Media Salli Schwartz Brad Lotterman [email protected] [email protected] [email protected] [email protected] Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology comp
April 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 ResMed Inc. (Exact Name UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
April 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 ResMed Inc. (Exact Name UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
April 30, 2026	EX-99.1	Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 [email protected] [email protected] Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026 • Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis • GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% • GAAP income from operations increased 17%;
January 30, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 29, 2026	EX-99.1	Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 [email protected] [email protected] Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 • Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis • Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% • Income from operations increased 18%; non-GAAP
January 29, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 ResMed Inc. (Exact Nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
November 21, 2025	S-8	As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 ResMed Inc. (Exact name of registrant As filed with the Securities and Exchange Commission on November 21, 2025 Registration No.
November 21, 2025	S-8	As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 ResMed Inc. (Exact name of registrant As filed with the Securities and Exchange Commission on November 21, 2025 Registration No.
November 21, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 ResMed Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-8 ResMed Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.004 per share Rule 457(h)
November 21, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 ResMed Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-8 ResMed Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.004 per share Rule 457(h)
November 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 19, 2025 Date of Report (Date of earliest event reported) ResMed Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 19, 2025 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
October 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 ResMed Inc. (Exact Nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
October 30, 2025	EX-99.1	Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 [email protected] [email protected] Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 • Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis • Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% • Income from operations increased 15%; non-GAAP i
October 7, 2025	144	144 144 0001881922 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
October 7, 2025	144	144 144 0001485164 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
October 2, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  Filed by a Party other than the Registrant  Check the app resmedincdefa14a2025xna UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 2, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi
October 2, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
October 1, 2025	144	144 144 0001346064 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
October 1, 2025	144	144 144 0001982205 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
September 8, 2025	144	144 144 0001485164 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
September 2, 2025	144	144 144 0001346064 XXXXXXXX LIVE 0000943819 RESMED INC 001-15317 9001 SPECTRUM CENTER BLVD.
August 18, 2025	EX-99.1	Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio EX-99.1 Exhibit 99.1 For investors For media +1 858.836.5971 +1 619.510.1281 [email protected] [email protected] Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio • Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations • Her appointment brings over 30 years of strategic, comme
August 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 ResMed Inc. (Exact Name UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
August 8, 2025	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2025 The following is a list of subsidiaries of ResMed Inc. as of June 30, 2025, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Ltd United Kingdom ResMed Asi
August 8, 2025	EX-10.7	Form of Restricted Stock Unit Award Agreement for Directors. Exhibit 10.7 ResMed Inc. Summary for Restricted Stock Unit Award Agreement 1. Participant Name: [ParticipantName] 2. Grant Date: [GrantDate] 3. Total Number of RSUs Granted: [QuantityGranted] 4. Vesting Schedule. Subject to the terms of the Agreement, the RSUs shall vest and become nonforfeitable at the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first an
August 8, 2025	EX-10.11	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.11 ResMed Inc. Summary for Performance-Based Restricted Stock Unit (“PSU”) Award Agreement 1.Holder. [PARTICIPANTNAME] 2.Grant Date [GRANTDATE] 3.Target Number of PSUs: [QuantityGranted] 4.Maximum Number of PSUs: 200% of Target Number of PSUs 5.Performance Period: [GRANTDATE] through [VestDate1] 6.Vesting Schedule. Subject to the terms of the Agreement, including the terms requiring the
August 8, 2025	EX-10.8	Form of Stock Option Award Agreement for Executive Officers. Exhibit 10.8 ResMed Inc. Summary for Executive Stock Option Award Agreement 1.Grantee [PARTICIPANTNAME] 2.Grant Date [GRANTDATE] 3.Number of Options [QuantityGRANTED] 4.Vesting Schedule. Subject to the terms of the Agreement, one-third of the options granted shall vest and become nonforfeitable on each of the first three anniversaries of the Grant Date. [VestingDateandQuantity] RESMED INC. EXECUTI
August 8, 2025	EX-3.2	Amended and Restated Bylaws of ResMed Inc. Exhibit 3.2 NINTH AMENDED AND RESTATED BYLAWS OF RESMED INC., A DELAWARE CORPORATION As Approved and Adopted by Board Resolution August 6, 2025 Internal Use TABLE OF CONTENTS Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings; Conduct of Meetings 1 Section 4. Notice of Meetings; Adjourned Meetings 1 Section 5. Waiver of
August 8, 2025	EX-10.12	Form of Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.12 ResMed Inc. Summary for Restricted Stock Unit Award Agreement (Designated Executives) 1.Holder. [PARTICIPANTNAME] 2.Grant Date. [GRANTDATE] 3.Number of RSUs. [QuantityGRANTED] 4.Vesting Schedule. Subject to the terms of the Agreement, including the terms requiring the satisfaction of a specified Performance Condition, the RSUs shall vest and become nonforfeitable in three equal insta
August 8, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 Commission file number: 001-15317 ResMe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 8, 2025	EX-10.10	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.10 ResMed Inc. Summary for Performance-Based Restricted Stock Unit (“PSU”) Award Agreement 1.Holder. [PARTICIPANTNAME] 2.Grant Date [GRANTDATE] 3.Target Number of PSUs: [QuantityGranted] 4.Maximum Number of PSUs: 200% of Target Number of PSUs 5.Performance Period: [GRANTDATE] through November 19, 2028 6.Vesting Schedule. Subject to the terms of the Agreement, including the terms requiri
August 8, 2025	EX-10.9	Form of Stock Option Award Agreement for Directors. Exhibit 10.9 ResMed Inc. Summary for Director Stock Option Award Agreement 1.Name of Participant: [ParticipantName] 2.Date of Grant: [GrantDate] 3.Grant Price: [GrantPrice] 4.Options Granted: [QuanityGranted] 5.Expiration Date: [ExpirationDate] Vesting Schedule. Subject to the terms of the Agreement, the Options shall vest and become exercisable at the earlier of (i) the first November 11 followin
August 1, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Em
July 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 ResMed Inc. (Exact Name o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Em
July 31, 2025	EX-99.1	Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 • Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19% • Operating cash flow of $539 million • Quarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s
May 29, 2025	EX-1.01	For the Reporting Period from January 1, 2024 through December 31, 2024 EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2024 through December 31, 2024 ResMed prepared this conflict minerals report for the reporting period from January 1, 2024 through December 31, 2024 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose information about the sources for tantalum, tin, tun
May 29, 2025	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission Fi SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) Michae
April 24, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 24, 2025	EX-10.1	Updated Form of Executive Agreement. Exhibit 10.1 EXECUTIVE AGREEMENT Executive Officer This Executive Agreement (this “Agreement”) is made effective as of the of , 20 (the “Effective Date”) between ResMed Inc., a Delaware corporation (the “Company”) and (“Executive”). WHEREAS, the Executive is currently employed as an executive officer of the Company; and WHEREAS, the Company believes it to be in the best interests of its stockholde
April 23, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
April 23, 2025	EX-99.1	– More – EX-99.1 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 • Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13% • Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m.
January 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 30, 2025	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 EX-99.1 2 d888970dex991.htm EX-99.1 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 – Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19% – Operating cash flow of $309 million Note: A webcast of ResMed’s conference call w
January 30, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
November 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2024 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
October 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 25, 2024	EX-10.1	Employee Director Deferral Progr Exhibit 10.1 RESMED INC. NON-EMPLOYEE DIRECTOR DEFERRAL PROGRAM (Adopted Effective as of August 16, 2024) ARTICLE I—PURPOSE The purpose of this ResMed Inc. Non-Employee Director Deferral Program (the “Program”) is to provide non-employee directors (“Directors”) on the Board of Directors (the “Board”) of ResMed Inc. (the “Company”) with the opportunity to defer settlement of awards of restricted st
October 24, 2024	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025 • Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27% • Operating cash flow of $326 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET toda
October 24, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
October 3, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
October 3, 2024	DEFA14A	US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  Filed by a Party other than the Regist US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  De
October 3, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi
August 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
August 16, 2024	EX-99.1	ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board Exhibit 99.1 For investors For media +1 858.836.5971 +1 619.510.1281 [email protected] [email protected] ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board • DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the world • Board appointment brings over 30 years o
August 9, 2024	EX-19	Insider Trading Policy and Guidelines Exhibit 19 Insider Trading Policy – 10b5-1 Effective August 17, 2023 1. Purpose To define the ResMed Inc. (“ResMed”) policy on trades and other transactions in “ResMed Securities,” which includes ResMed common stock, options, futures, calls, puts, warrants, debt securities, and any other rights to acquire ResMed common stock. 2. Scope This policy applies worldwide, to all ResMed Directors, Executi
August 9, 2024	EX-4.2	Description of ResMed Inc.’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EXHIBIT 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 ResMed Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following summary of the terms of our common stock is based upon our First Restated Ce
August 9, 2024	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2024 The following is a list of subsidiaries of ResMed Inc. as of June 30, 2024, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Ltd United Kingdom ResMed Asi
August 9, 2024	EX-97	Compensation Recovery Policy. Exhibit 97 ResMed Inc. Compensation Recovery Policy This Compensation Recovery Policy (the “Policy”) is intended to maintain a culture of focused, diligent, and responsible management and to ensure compliance with applicable laws by ResMed Inc., its subsidiaries, and affiliates (together, “ResMed”). ResMed has adopted this Policy, effective as of October 2, 2023 (the “Effective Date”). Capitalized
August 9, 2024	EX-10.5	Amended and Restated ResMed Inc. Deferred Compensation Plan. Exhibit 10.5 AMENDED AND RESTATED RESMED INC. DEFERRED COMPENSATION PLAN, As Amended Through August 17, 2023 EFFECTIVE DATE July 1, 2010 1 TABLE OF CONTENTS Page ARTICLE I Establishment and Purpose 2 ARTICLE II Definitions 3 ARTICLE III Eligibility and Participation 10 ARTICLE IV Deferrals 11 ARTICLE V Employer Contributions 14 ARTICLE VI Benefits 15 ARTICLE VII Modifications to Payment Schedules
August 9, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 Commission file number: 001-15317 ResMe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 1, 2024	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024 • Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30% • Operating cash flow of $440 million • Quarterly dividend increases 10% to $0.53 per share • Company to host an Investo
August 1, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
May 30, 2024	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction (Commission (I.R.S. Employer of SD SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) Mic
May 30, 2024	EX-1.01	For the Reporting Period from January 1, 2023 through December 31, 2023 EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2023 through December 31, 2023 ResMed prepared this conflict minerals report for the reporting period from January 1, 2023 through December 31, 2023 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose information about the sources for tantalum, tin, tun
April 26, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 25, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
April 25, 2024	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 • Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23% • Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET toda
February 13, 2024	SC 13G/A	RMD / ResMed Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01814-resmedinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: ResMed Inc Title of Class of Securities: Common Stock CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pur
January 25, 2024	SC 13G/A	RMD / ResMed Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us7611521078012524.txt us7611521078012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
January 25, 2024	EX-10.1	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers Exhibit 10.1 ResMed Inc. Summary for Performance-Based Restricted Stock Unit (“PSU”) Award Agreement 1. Holder. [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Target Number of PSUs: [PSUs GRANTED] 4. Maximum Number of PSUs: 200% of Target Number of PSUs 5. Performance Period: [GRANT DATE through [THIRD YEAR ANNIVERSARY] 6. Vesting Schedule. Subject to the terms of the Agreement, including the te
January 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 24, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
January 24, 2024	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 – Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20% – Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call
November 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2023 Date of Report (Date of earliest event reported) ResMed Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2023 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
November 20, 2023	EX-3.1	Eighth Amended and Restated Bylaws of ResMed Inc., as adopted on November 17, 2023 (as Approved and Adopted by Board Resolution November 17, 2023). (Incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 8-K filed on November 20, 2023) Exhibit 3.1 EIGHTH AMENDED AND RESTATED BYLAWS OF RESMED INC., A DELAWARE CORPORATION As Approved and Adopted by Board Resolution November 17, 2023 Internal Use TABLE OF CONTENTS Page ARTICLE I. MEETINGS OF STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings 1 Section 4. Notice of Meetings; Adjourned Meetings 1 Section 5. Waiver of Notice 2 Section
November 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
November 9, 2023	EX-99.1	ResMed Adopts New Operating Model to Accelerate Long-term Growth Exhibit 99.1 For media +1 858-836-6798 [email protected] For investors +1 858.836.5000 [email protected] ResMed Adopts New Operating Model to Accelerate Long-term Growth - Justin Leong appointed Chief Product Officer, effective immediately. - Katrin Pucknat appointed Chief Marketing Officer, effective immediately. - Mike Fliss appointed Chief Revenue Officer, effective immediately. - Rob
October 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 26, 2023	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024 Exhibit 99.1 For investors For media +1 858-836-5000 +1 858-289-7272 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024 • Year-over-year revenue grows 16%, operating profit up 5%, non-GAAP operating profit up 10% • Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed’s conference call will
October 26, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
October 13, 2023	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi
October 5, 2023	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
October 5, 2023	DEFA14A	US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registra US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive P
October 5, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi
August 11, 2023	EX-10.10	Form of Executive Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.10 ResMed Inc. Summary for Restricted Stock Unit Award Agreement (Designated Executives) 1. Holder. [PARTICIPANT NAME] 2. Grant Date. [GRANT DATE] 3. Number of RSUs. [TOTAL NUMBER OF RSUs GRANTED] 4. Vesting Schedule. Subject to the terms of the Agreement, including the terms requiring the satisfaction of a specified Performance Condition, the RSUs shall vest and become nonforfeitable i
August 11, 2023	EX-10.7	Form of Stock Option Grant for Executive Officers. Exhibit 10.7 ResMed Inc. Summary for Executive Stock Option Award Agreement 1. Grantee [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Number of Options: [OPTIONS GRANTED] 4. Vesting Schedule. Subject to the terms of the Agreement, one-third of the options granted shall vest and become nonforfeitable on each of the first three anniversaries of the Grant Date. RESMED INC. EXECUTIVE STOCK OPTION AG
August 11, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 Commission file number: 001-15317 ResMe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 11, 2023	EX-10.9	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.9 ResMed Inc. Summary for Performance-Based Restricted Stock Unit (“PSU”) Award Agreement 1. Holder. [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Target Number of PSUs: [PSUs GRANTED] 4. Maximum Number of PSUs: 200% of Target Number of PSUs 5. Performance Period: [GRANT DATE through [FOURTH YEAR ANNIVERSARY]] 6. Vesting Schedule. Subject to the terms of the Agreement, including the
August 11, 2023	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2023 The following is a list of subsidiaries of ResMed Inc. as of June 30, 2023, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Ltd United Kingdom ResMed Asi
August 3, 2023	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023 EX-99.1 Exhibit 99.1 For investors For media +1 858-836-5000 +1 858-289-7272 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023 – Year-over-year revenue grows 23%, operating profit up 8%, non-GAAP operating profit up 13% – Quarterly dividend increases 9% to $0.48 per share Note: A webcast of ResMed’s conference call will be availab
August 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
July 6, 2023	SC 13G/A	NYXH / Nyxoah SA / RESMED INC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
May 26, 2023	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission Fi SD SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) Dav
May 26, 2023	EX-1.01	For the Reporting Period from January 1, 2022 through December 31, 2022 EX-1.01 2 d515282dex101.htm EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2022 through December 31, 2022 ResMed prepared this conflict minerals report for the reporting period from January 1, 2022 through December 31, 2022 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose information about the so
April 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 27, 2023	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023 – Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27% EX-99.1 Exhibit 99.1 For investors +1 858-836-5000 [email protected] For media +1 858-836-6798 [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023 – Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.co
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 ResMed Inc. (Exact Name UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
April 6, 2023	SC 13G	NYXH / Nyxoah SA / RESMED INC - SC 13G Passive Investment SC 13G CUSIP No. B6S7WD106 13G Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
March 30, 2023	EX-99.1	ResMed Chief Administrative Officer and Global General Counsel to Retire EX-99.1 Exhibit 99.1 For media For investors [email protected] [email protected] +1 858.836.6798 +1 858.836.5000 ResMed Chief Administrative Officer and Global General Counsel to Retire • ResMed to conduct an internal search for a successor general counsel • Amy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, M
March 30, 2023	8-K	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 ResMed Inc. (Exact Name of Registrant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identi
February 10, 2023	SC 13G/A	RMD / ResMed Inc. / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ResMed Inc. (Name of Issuer) Common (Title of Class of Securities) 761152107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
February 9, 2023	SC 13G/A	RMD / ResMed Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: ResMed Inc. Title of Class of Securities: Common Stock and CDI CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 7, 2023	SC 13G/A	RMD / ResMed Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us7611521078020723.txt us7611521078020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
January 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 ResMed Inc. (Exact Nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
January 26, 2023	EX-99.2	ResMed appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to become Chair Emeritus EX-99.2 Exhibit 99.2 For investors For media Amy Wakeham Jayme Rubenstein +1 858.836.5000 +1 858.836.6798 [email protected] [email protected] ResMed appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to become Chair Emeritus SAN DIEGO, January 26, 2023 – ResMed (NYSE: RMD, ASX: RMD) today announced ResMed’s board of directors has appointed chief executive officer Mi
January 26, 2023	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023 – Year-over-year revenue grows 16%, operating profit up 13%, non-GAAP operating profit up 14% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET toda
November 17, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2022 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
October 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 27, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
October 27, 2022	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023 – Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4% Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023 ? Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4% Note: A webcast of ResMed?s conference call will be available at 4:30 p.m. ET today at http://
October 5, 2022	DEFA14A	US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registra US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive P
October 5, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi
August 12, 2022	EX-10.7	Form of Stock Option Grant for Executive Officers. Exhibit 10.7 ResMed Inc. Summary for Executive Stock Option Award Agreement 1. Grantee [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Number of Options: [OPTIONS GRANTED] 4. Vesting Schedule. Subject to the terms of the Agreement, one-third of the options granted shall vest and become nonforfeitable on each of the first three anniversaries of the Grant Date. RESMED INC. EXECUTIVE STOCK OPTION AG
August 12, 2022	EX-10.6	Form of Restricted Stock Unit Award Agreement for Directors. (Incorporated by reference to Exhibit 10.6 to the Registrant’s Report on Form 10-K filed on August 12, 2022) Exhibit 10.6 Non-Employee Directors ResMed Inc. Summary for Restricted Stock Unit Award Agreement 1.Participant Name: [PARTICIPANT NAME] 2.Grant Date: [GRANT DATE] 3.Total Number of RSUs Granted: [QUANTITY GRANTED] 4.Vesting Schedule. Subject to the terms of the Agreement, the RSUs shall vest and become nonforfeitable at the earlier of (i) the first November 11 following the Grant Date, or (ii) th
August 12, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 Commission file number: 001-15317 ResMe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 12, 2022	EX-10.3	Updated Form of Executive Agreement. (Incorporated by reference to Exhibit 10.3 to the Registrant’s Report on Form 10-K filed on August 12, 2022) Exhibit 10.3 EXECUTIVE AGREEMENT Executive Officer This Executive Agreement (this ?Agreement?) is made effective as of the day of , 20 (the ?Effective Date?) between ResMed Inc., a Delaware corporation and its subsidiaries (collectively, the ?Company?) and (?Executive?). WHEREAS, the Company currently employs Executive as an executive officer of the Company; and WHEREAS, the Company believes it to
August 12, 2022	8-K/A	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R
August 12, 2022	EX-10.10	Form of Executive Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.10 ResMed Inc. Summary for Restricted Stock Unit Award Agreement (Designated Executives) 1. Holder. [PARTICIPANT NAME] 2. Grant Date. [GRANT DATE] 3. Number of RSUs. [TOTAL NUMBER OF RSUs GRANTED] 4. Vesting Schedule. Subject to the terms of the Agreement, including the terms requiring the satisfaction of a specified Performance Condition, the RSUs shall vest and become nonforfeitable i
August 12, 2022	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2022 The following is a list of subsidiaries of ResMed Inc. as of June 30, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Ltd United Kingdom ResMed Asi
August 12, 2022	EX-10.9	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. Exhibit 10.9 ResMed Inc. Summary for Performance-Based Restricted Stock Unit (?PSU?) Award Agreement 1. Holder. [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Target Number of PSUs: [PSUs GRANTED] 4. Maximum Number of PSUs: 225% of Target Number of PSUs 5. Performance Period: [GRANT DATE through [FOURTH YEAR ANNIVERSARY]] 6. Vesting Schedule. Subject to the terms of the Agreement, including the
August 12, 2022	EX-10.8	Form of Stock Option Grant for Directors. (Incorporated by reference to Exhibit 10.8 to the Registrant’s Report on Form 10-K filed on August 12, 2022) Exhibit 10.8 ResMed Inc. Summary for Director Stock Option Award Agreement 1.Name of Participant: [PARTICIPANT NAME] 2.Date of Grant: [GRANT DATE] 3.Grant Price: [GRANT PRICE] 4.Options Granted: [QUANTITY GRANTED] 5.Expiration Date: [EXPIRATION DATE] Vesting Schedule. Subject to the terms of the Agreement, the Options shall vest and become exercisable at the earlier of (i) the first November 11 fo
August 11, 2022	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022 ? Year-over-year revenue grows 4%, operating profit up 6%, non-GAAP operating profit up 4% ? Quarterly dividend increases 5% to $0.44 per share Note: A webcast of ResMed?s conference c
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
July 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identif
July 1, 2022	EX-99.1	ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care Exhibit 99.1 For media For investors Jayme Rubenstein Amy Wakeham +1 858.836.6798 +1 858.836.5000 [email protected] [email protected] ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care - Blaise is a medtech industry thought leader with over 25 years? experience - A board member of MedTech Europe since 2020; President of the Snitem, France?s premier medtech association -
June 30, 2022	EX-10.3	Second Amendment to Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement, dated as of June 29, 2022, by and among ResMed Pty Limited, as borrower, ResMed, Inc., the other parties party thereto, and MUFG Union Bank, N.A., as administrative agent. (Incorporated by reference to Exhibit 10.3 to the Registrant’s Report on Form 8-K filed on June 29, 2022) Exhibit 10.3 Execution Version SECOND AMENDMENT TO SYNDICATED FACILITY AGREEMENT AND FIRST AMENDMENT TO UNCONDITIONAL GUARANTY This SECOND AMENDMENT TO SYNDICATED FACILITY AGREEMENT AND FIRST AMENDMENT TO UNCONDITIONAL GUARANTY (this ?Amendment?) is dated as of June 29, 2022, and effective in accordance with Section 6 below, by and among RESMED PTY LIMITED, a company incorporated in the Commonweal
June 30, 2022	EX-10.1	Second Amended and Restated Credit Agreement dated as of June 29, 2022, by and among ResMed Inc., as borrower, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank Australia Limited, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, Wells Fargo Bank, National Association, as documentation agent, and each of the lenders identified therein. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Report on Form 8-K filed on June 29, 2022) Exhibit 10.1 Execution Version SECOND AMENDED AND RESTATED CREDIT AGREEMENT Dated as of June 29, 2022 Among RESMED INC., as Borrower, MUFG UNION BANK, N.A., as Administrative Agent, Joint Lead Arranger, Sole Book Runner, Swing Line Lender and L/C Issuer, WESTPAC BANKING CORPORATION, as Syndication Agent and Joint Lead Arranger, HSBC BANK AUSTRALIA LIMITED, as Syndication Agent and Joint Lead Arran
June 30, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identif
June 30, 2022	EX-10.2	Second Amended and Restated Unconditional Guaranty dated as of June 29, 2022, by each of the Revolving Facility Guarantors, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Revolving Credit Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant’s Report on Form 8-K filed on June 29, 2022) Exhibit 10.2 Execution Version SECOND AMENDED AND RESTATED UNCONDITIONAL GUARANTY THIS SECOND AMENDED AND RESTATED UNCONDITIONAL GUARANTY (?Guaranty?) is entered into as of June 29, 2022, by each of the undersigned (each a ?Guarantor?), in favor of MUFG UNION BANK, N.A. (and its subsidiaries and affiliates), in its capacity as Administrative Agent (?Agent?). Recitals A. This Guaranty is entered in
June 14, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identif
June 14, 2022	EX-99.1	ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Exhibit 99.1 For media For media Jayme Rubenstein Laura Willig +1 858.836.6798 +49 51 21 / 28 29 1-808 [email protected] [email protected] For investors Amy Wakeham +1 858.836.5000 [email protected] ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions ? Acquisition creates a global leader in out-of-hospital software solutions ? Accelerates ResMed?s Saa
June 14, 2022	EX-99.2	Forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial informa Acquisition of MEDIFOX DAN June 14, 2022 Exhibit 99.2 Forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States,
May 26, 2022	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission Fi SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) David
May 26, 2022	EX-1.01	For the Reporting Period from January 1, 2021 through December 31, 2021 EX-1.01 2 d300651dex101.htm EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2021 through December 31, 2021 ResMed prepared this conflict minerals report for the reporting period from January 1, 2021 through December 31, 2021 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose information about the so
May 11, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identific
May 11, 2022	EX-99.1	ResMed Announces Leadership Change Exhibit 99.1 For media For investors Jayme Rubenstein Amy Wakeham +1 858-836-6798 +1 858.836.5000 [email protected] [email protected] ResMed Announces Leadership Change SAN DIEGO, May 5, 2022 ? ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effect
April 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 28, 2022	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 – Year-over-year revenue grows 12%, operating profit up 5%, non-GAAP operating profit up 5% Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 ? Year-over-year revenue grows 12%, operating profit up 5%, non-GAAP operating profit up 5% Note: A webcast of ResMed?s conference call will be available at 4:30 p.m. ET today at http:/
April 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. E
February 10, 2022	SC 13G/A	RMD / ResMed Inc. / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ResMed Inc. (Name of Issuer) Common (Title of Class of Securities) 791152107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
February 10, 2022	SC 13G/A	RMD / ResMed Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: ResMed Inc. Title of Class of Securities: Common Stock and CDI CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 1, 2022	SC 13G/A	RMD / ResMed Inc. / BlackRock Inc. Passive Investment us7611521078020122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 28, 2022	EX-10.1	Separation Agreement and General Release of Claims, dated September 29, 2021, by and between Rajwant Sodhi and ResMed Inc., including Consulting Agreement, as Exhibit A, effective as of September 2, 2021. SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAiMS This Separation Agreement and General Release of All Claims (?Agreement?) is made by and between ResMed Inc.
January 27, 2022	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2022 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2022 ? Year-over-year revenue grows 12%, operating profit up 12%, non-GAAP operating profit up 5% Note: A webcast of ResMed?s conference call will be available at 4:30 p.m. ET today at http
January 27, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
November 19, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 18, 2021 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
October 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 28, 2021	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022 - Year-over-year revenue grows 20%, operating profit up 21%, non-GAAP operating profit up 18% Note: A webcast of ResMed?s conference call will be available at 4:30 p.m. ET today at http
October 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S.
October 7, 2021	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Ide
October 6, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta
October 6, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
September 13, 2021	EX-3.1	Seventh Amended and Restated Bylaws of ResMed Inc., a Delaware Corporation (as Approved and Adopted by Board Resolution September 10, 2021) (Incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 8-K filed on September 13, 2021) Exhibit 3.1 SEVENTH AMENDED AND RESTATED BYLAWS OF RESMED INC., A DELAWARE CORPORATION As Approved and Adopted by Board Resolution September 10, 2021 TABLE OF CONTENTS Page ARTICLE I. MEETINGS OF STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings 1 Section 4. Notice of Meetings; Adjourned Meetings 1 Section 5. Waiver of Notice 2 Section 6. Qualifi
September 13, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 10, 2021 Date of Report (Date of earliest event reported) RESMED INC. (Exact name of registrant as specified in its charter) DELAWARE 001-15317 98-0152841 (State or other jurisdiction of incorporation) (Commission File Numb
August 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Ident
August 19, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 Commission file numbe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization
August 17, 2021	EX-10.10	Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. EXHIBIT 10.10 ? ResMed Inc. ? Summary for Performance-Based Restricted Stock Unit (?PSU?) Award Agreement 1. Holder. [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Target Number of PSUs: [PSUs GRANTED] 4. Maximum Number of PSUs: 225% of Target Number of PSUs 5. Performance Period: [GRANT DATE through [FOURTH YEAR ANNIVERSARY] 6. Vesting Schedule Subject to the terms of the Agreement, including t
August 17, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 Commission file number: 001-15317 ResMe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 17, 2021	EX-10.11	Form of Executive Restricted Stock Unit Award Agreement for Executive Officers. EXHIBIT 10.11 ? ResMed Inc. Summary for Restricted Stock Unit Award Agreement (Designated Executives) ? 1. Holder. [PARTICIPANT NAME] 2. Grant Date [GRANT DATE] 3. Number of RSUs: [TOTAL NUMBER OF RSUs GRANTED] 4. Vesting Schedule: Subject to the terms of the Agreement, including the terms requiring the satisfaction of a specified Performance Condition, the RSUs shall vest and become nonforfeitabl
August 17, 2021	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 ? RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2021 ? ? The following is a list of subsidiaries of ResMed Inc. as of June 30, 2021, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. ? ? Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Ltd United Kingdom
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identi
August 5, 2021	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021 ? Year-over-year revenue grows 14%, operating profit up 8%, non-GAAP operating profit up 7% ? Quarterly dividend increases 8% to $0.42 per share ? Company to host a virtual Investor Da
May 26, 2021	EX-1.01	For the Reporting Period from January 1, 2020 through December 31, 2020 Exhibit 1.01 ? Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2020 through December 31, 2020 ResMed prepared this conflict minerals report for the reporting period from January 1, 2020 through December 31, 2020 to comply with Exchange Act Rule 13p-1 (?rule?). The rule requires ResMed to annually disclose information about the sources for tantalum, tin, tungsten, a
May 26, 2021	SD	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission Fi SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) David
May 21, 2021	S-8	As filed with the Securities and Exchange Commission on May 21, 2021 As filed with the Securities and Exchange Commission on May 21, 2021 Registration No.
May 21, 2021	EX-4.4	ResMed Inc. Deferred Compensation Plan. EXHIBIT 4.4 ? ? ? ? AMENDED AND RESTATED ? ? ? RESMED INC. ? ? ? DEFERRED COMPENSATION PLAN, As Amended Through May 21, 2020 ? ? ? EFFECTIVE DATE July 1, 2010 ? TABLE OF CONTENTS ? ? Page ARTICLE I Establishment and Purpose 1 ARTICLE II Definitions 1 ARTICLE III Eligibility and Participation 8 ARTICLE IV Deferrals 9 ARTICLE V Employer Contributions 12 ARTICLE VI Benefits 13 ARTICLE VII Modificatio
April 30, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identi
April 29, 2021	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2021 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2021 ? Year-over-year operating profit up 3%, non-GAAP operating profit up 2% Note: A webcast of ResMed?s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.co
April 16, 2021	TEXT-EXTRACT	TEXT-EXTRACT United States securities and exchange commission logo April 16, 2021 Brett Sandercock Chief Financial Officer ResMed Inc.
April 16, 2021	LETTER	LETTER United States securities and exchange commission logo April 16, 2021 Brett Sandercock Chief Financial Officer ResMed Inc.
March 30, 2021	10-K/A	Annual Report - 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization
March 29, 2021	CORRESP	March 29, 2021 March 29, 2021 ? Mr. David Burton Office of Life Sciences Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 ? Re: ResMed Inc. Form 10-K for the Fiscal Year Ended June 30, 2020 File No. 001-15317 Filed August 13, 2020 ? Dear Mr. Burton, ? ResMed (the ?Company?, ?we?, ?us? or ?our?) has the following response to the comment of the staff of
February 26, 2021	TEXT-EXTRACT	TEXT-EXTRACT United States securities and exchange commission logo February 26, 2021 Brett Sandercock Chief Financial Officer ResMed Inc.
February 26, 2021	LETTER	LETTER United States securities and exchange commission logo February 26, 2021 Brett Sandercock Chief Financial Officer ResMed Inc.
February 10, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ResMed Inc. (Name of Issuer) Common (Title of Class of Securities) 791152107 (CUSIP Number) December 31, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ResMed Inc. (Name of Issuer) Common (Title of Class of Securities) 791152107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: ResMed Inc. Title of Class of Securities: Common Stock CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
February 1, 2021	SC 13G/A	SC 13G/A us7611521078013121.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 28, 2021	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2021 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2021 – Year-over-year revenue grows 9%, operating profit up 12%, non-GAAP operating profit up 16% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today
January 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Iden
November 20, 2020	8-K	Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 19, 2020 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
November 5, 2020	8-K/A	Other Events - 8-K/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Id
October 30, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 29, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Iden
October 29, 2020	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2021 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2021 • Year-over-year revenue grows 10%, non-GAAP operating profit up 24% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resme
October 6, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 6, 2020	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
August 13, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS
August 13, 2020	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2020 The following is a list of subsidiaries of ResMed Inc. as of June 30, 2020, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (UK) Limited United King
August 13, 2020	S-8	- S-8 As filed with the Securities and Exchange Commission on August 13, 2020 Registration No.
August 13, 2020	EX-4.2	Description of ResMed Inc.’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EXHIBIT 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 ResMed Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon our First Restated Certificate of Incorpor
August 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identi
August 5, 2020	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020 – Year-over-year revenue grows 9%, non-GAAP operating profit up 24% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resme
May 22, 2020	SD	- SD SD SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices) Dav
May 22, 2020	EX-1.01	For the Reporting Period from January 1, 2019 through December 31, 2019 May 22, 2020 EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2019 through December 31, 2019 May 22, 2020 ResMed prepared this conflict minerals report for the reporting period from January 1, 2019 through December 31, 2019 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose whether the tantalum, tin, tungsten, an
May 1, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
April 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identi
April 30, 2020	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2020 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2020 - Year-over-year revenue grows 16%, non-GAAP operating profit up 31% - Balanced growth across product portfolio, software solutions, and global markets - Focused on combating CO
February 26, 2020	EX-3.1	Sixth Amended and Restated Bylaws of ResMed Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 26, 2020) EX-3.1 Exhibit 3.1 SIXTH AMENDED AND RESTATED BYLAWS OF RESMED INC., A DELAWARE CORPORATION As Approved and Adopted by Board Resolution February 21, 2020 TABLE OF CONTENTS Page ARTICLE I. MEETINGS OF STOCKHOLDERS 3 Section 1. Annual Meeting 3 Section 2. Special Meetings 3 Section 3. Place of Meetings 3 Section 4. Notice of Meetings; Adjourned Meetings 3 Section 5. Waiver of Notice 4 Section 6. Qua
February 26, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2020 Date of Report (Date of earliest event reported) RESMED INC. (Exact name of registrant as specified in its charter) DELAWARE 001-15317 98-0152841 (State or other jurisdiction of incorporation) (Commission File Numbe
February 12, 2020	SC 13G/A	RMD / ResMed Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: ResMed Inc Title of Class of Securities: Common Stock CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d
February 7, 2020	SC 13G/A	RMD / ResMed Inc. / FMR LLC / Fidelity Passive Investment SCHEDULE 13G Amendment No. 2 RESMED INC COMMON STOCK Cusip #761152107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #761152107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 842,430 Item 6: 0 Item 7: 6,182,087 Item 8: 0 Item 9: 6,182,087 Item 11: 4.299% Item
February 6, 2020	SC 13G/A	RMD / ResMed Inc. / BlackRock Inc. Passive Investment us7611521078020520.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 5, 2020	SC 13G	RMD / ResMed Inc. / WCM INVESTMENT MANAGEMENT/CA - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ResMed Inc. (Name of Issuer) Common (Title of Class of Securities) 791152107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
January 31, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Iden
January 30, 2020	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2020 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2020 • Year-over-year revenue grows 13%, non-GAAP operating profit up 21% • Balanced growth across product portfolio, software solutions, and global markets Note: A webcast of ResMe
November 22, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 21, 2019 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
October 25, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
October 24, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Iden
October 24, 2019	EX-99.1	ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2020 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2020 • Year-over-year revenue grows 16%, non-GAAP operating profit up 22% • Balanced growth across product portfolio and global markets Note: A webcast of ResMed’s conference call wi
October 8, 2019	DEFA14A	RMD / ResMed Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 8, 2019	DEF 14A	RMD / ResMed Inc. DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
August 8, 2019	EX-21.1	Subsidiaries of the Registrant. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2019 Company Jurisdiction of Formation ResMed Corp. Minnesota ResMed (Malaysia) Sdn Bhd Malaysia ResMed (UK) Limited United Kingdom ResMed (EPN) Limited United Kingdom ResMed Asia Pacific Pty Limited Australia ResMed Beteiligungs GmbH Germany ResMed Finland OY Finland ResMed Holdings Pty Limited Australia ResMed Hong Ko
August 8, 2019	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 Commission file number: 001-15317 ResMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IR
July 25, 2019	EX-99.1	ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2019 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2019 – Year-over-year revenue grows 13%, gross margin improves 120 basis points, non-GAAP operating profit up 18% – Quarterly dividend increases 5% to $0.39 per share – ResMed well-
July 25, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2019 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Ide
July 15, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number)
July 15, 2019	EX-10.1	Note Purchase Agreement, dated July 10, 2019 by and among ResMed Inc. and the purchasers party to that agreement (including form of 3.24% Series A Senior Note due 2026, form of Series B 3.45% Senior Note due 2029, and form of Subsidiary Guaranty Agreement). EX-10.1 Exhibit 10.1 EXECUTION VERSION RESMED INC. $500,000,000 $250,000,000 3.24% Series A Senior Notes due July 10, 2026 $250,000,000 3.45% Series B Senior Notes due July 10, 2029 NOTE PURCHASE AGREEMENT Dated as of July 10, 2019 TABLE OF CONTENTS SECTION HEADING PAGE Section 1. Authorization of Notes 1 Section 2. Sale and Purchase of Notes; Subsidiary Guaranty 1 Section 2.1. Sale and Purchase o
May 22, 2019	SD	RMD / ResMed Inc. SD - - SD SD 1 d752004dsd.htm SD SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Ex
May 22, 2019	EX-1.01	For the Reporting Period from January 1, 2018 through December 31, 2018 May 22, 2019 EX-1.01 Exhibit 1.01 — Conflict Minerals Report of ResMed Inc. For the Reporting Period from January 1, 2018 through December 31, 2018 May 22, 2019 ResMed prepared this conflict minerals report for the reporting period from January 1, 2018 through December 31, 2018 to comply with Exchange Act Rule 13p-1 (“rule”). The rule requires ResMed to annually disclose whether the tantalum, tin, tungsten, an
May 16, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2019 ResMed Inc.
May 3, 2019	10-Q	RMD / ResMed Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
May 2, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Ident
May 2, 2019	EX-99.1	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2019 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2019 Year-over-year revenue grows 12%, gross margin improves 100 basis points, operating profit up 15% MatrixCare contributes positively to revenue, gross margin, and profit Re
February 14, 2019	SC 13G/A	RMD / ResMed Inc. / Capital World Investors - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ResMed Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761152107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 13, 2019	SC 13G/A	RMD / ResMed Inc. / FMR LLC / Fidelity Passive Investment SCHEDULE 13G Amendment No. 1 RESMED INC COMMON STOCK Cusip #761152107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #761152107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 912,068 Item 6: 0 Item 7: 7,813,366 Item 8: 0 Item 9: 7,813,366 Item 11: 5.483% Item
February 11, 2019	SC 13G/A	RMD / ResMed Inc. / VANGUARD GROUP INC Passive Investment resmedinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7 )* Name of issuer: ResMed Inc Title of Class of Securities: Common Stock CUSIP Number: 761152107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate th
February 6, 2019	SC 13G/A	RMD / ResMed Inc. / BlackRock Inc. Passive Investment us7611521078020619.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) RESMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 761152107 - (CUSIP Number) December 31, 2018 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 1, 2019	10-Q	RMD / ResMed Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-15317 ResMed Inc.
January 30, 2019	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
January 30, 2019	EX-99.2	Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information On November 13, 2018, ResMed Operations Inc. (“ResMed Operations”) completed its previously announced acquisition of MatrixCare Holdings, Inc., a Delaware corporation (“MatrixCare”), in accordance with an Agreement and Plan of Merger (the “Merger Agreement”), dated November 5, 2018, with Evolved Sub, Inc. a Delaware corpor
January 29, 2019	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
January 29, 2019	EX-99.2	Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information On November 13, 2018, ResMed Operations Inc. (“ResMed Operations”) completed its previously announced acquisition of MatrixCare Holdings, Inc., a Delaware corporation (“MatrixCare”), in accordance with an Agreement and Plan of Merger (the “Merger Agreement”), dated November 5, 2018, with Evolved Sub, Inc. a Delaware corpor
January 29, 2019	EX-99.1	Independent Auditor’s Report EX-99.1 3 rmd-20181113xex991.htm EX-99.1 Exhibit 99.1 Independent Auditor’s Report Board of Directors MatrixCare Holdings, Inc. and Subsidiaries Report on the Financial Statements We have audited the accompanying consolidated financial statements of MatrixCare Holdings, Inc. and its subsidiaries (the Company), which comprise the consolidated balance sheet as of December 31, 2017, the related c
January 24, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer
January 24, 2019	EX-99.1	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019 EX-99.1 Exhibit 99.1 For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 [email protected] [email protected] ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019 • Year-over-year growth in revenue, gross margin, and operating profit • Well-positioned for future growth through further penetration of untreated sleep apnea and expanding po
November 16, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2018 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File
November 14, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2018 Date of Report (Date of earliest event reported) ResMed Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-15317 98-0152841 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

DE:RME	163,00 €
GB:0KW4	209,19 US$
AT:RMD	170,95 €
IT:1RMD	157,90 €

RMD / ResMed Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings